The Motley Fool··Jonathan PoncianoRTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline
RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.
ARGXAPLSMDGLINSMinstitutional investmentbiotech investment